World News: 13:19 GMT Friday 10th August 2018. [ASLAN Pharmaceuticals Limited via Globe Newswire via SPi World News]
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of recruitment of 52 patients for the phase 2 part of its global phase 2/3 study investigating as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients.
Initiated in 2017, the global phase 2/3 study is a double blind, randomised two-arm study that aims to determine the efficacy of in combination with mFOLFOX6 (a combination chemotherapy regimen) in comparison to mFOLFOX6 alone in the first line setting. Topline data for the phase 2 study is expected in Q4 2018.
Gastric cancer currently ranks fourth in cancer incidence worldwide, is the second most common cause of cancer-related deaths worldwide and is one of the most common types of cancer in Asia. has been granted Orphan Drug Designation status by the US FDA in gastric cancer in 2016.
This release and the accompanying financial information contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy, the Company’s plans to develop and commercialise its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company’s product candidates. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s prospectus dated May 8, 2018 filed with the US Securities and Exchange Commission on such date.
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Globe Newswire: 13:19 GMT Friday 10th August 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.